Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Among authors: kiehntopf m. Intensive Care Med. 2022 Mar;48(3):311-321. doi: 10.1007/s00134-021-06609-6. Epub 2022 Feb 1. Intensive Care Med. 2022. PMID: 35106617 Free PMC article. Clinical Trial.
Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S, Fiedler S, Hohn A, Brinkmann A, Frey OR, Hoyer H, Schlattmann P, Kiehntopf M, Roberts JA, Pletz MW; TARGET Study Group. Hagel S, et al. Among authors: kiehntopf m. Trials. 2019 Jun 6;20(1):330. doi: 10.1186/s13063-019-3437-x. Trials. 2019. PMID: 31171029 Free PMC article.
Correction to: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand MA, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Among authors: kiehntopf m. Intensive Care Med. 2022 May;48(5):646-647. doi: 10.1007/s00134-022-06668-3. Intensive Care Med. 2022. PMID: 35303118 Free PMC article. No abstract available.
Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründling M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T; German Study Group Competence Network Sepsis (SepNet). Brunkhorst FM, et al. Among authors: kiehntopf m. JAMA. 2012 Jun 13;307(22):2390-9. doi: 10.1001/jama.2012.5833. JAMA. 2012. PMID: 22692171 Clinical Trial.
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial.
Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Gründling M, Kluge S, Kaufmann I, Ott K, Quintel M, Jelschen F, Meybohm P, Rademacher S, Meier-Hellmann A, Utzolino S, Kaisers UX, Putensen C, Elke G, Ragaller M, Gerlach H, Ludewig K, Kiehntopf M, Bogatsch H, Engel C, Brunkhorst FM, Loeffler M, Reinhart K; for SepNet Critical Care Trials Group. Bloos F, et al. Among authors: kiehntopf m. JAMA Intern Med. 2016 Sep 1;176(9):1266-76. doi: 10.1001/jamainternmed.2016.2514. JAMA Intern Med. 2016. PMID: 27428731 Clinical Trial.
Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff.
Bahrs C, Kimmig A, Weis S, Ankert J, Hagel S, Maschmann J, Stallmach A, Steiner A, Bauer M, Behringer W, Baier M, Kesselmeier M, Richert C, Zepf F, Walter M, Scherag A, Kiehntopf M, Löffler B, Pletz MW. Bahrs C, et al. Among authors: kiehntopf m. Transbound Emerg Dis. 2022 Mar;69(2):720-730. doi: 10.1111/tbed.14041. Epub 2021 Mar 9. Transbound Emerg Dis. 2022. PMID: 33605549 Free PMC article.
183 results